Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary M Sandusky

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Hematology/Oncology Clinics of North America|November 26, 2022
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerAlbert Grinshpun, Zachary M Sandusky, Rinath Jeselsohn
Biochimica Et Biophysica Acta. Reviews on Cancer|November 6, 2022
ESR1 activating mutations: From structure to clinical applicationAlbert Grinshpun, Vincent Chen, Zachary M Sandusky, et al.
STAR Protocols|January 25, 2021
FACS protocol for direct comparison of cell populations isolated from miceKatarzyna A Ludwik, Zachary M Sandusky, Eric B Wright, et al.
Organic Letters|April 26, 2017
Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2Mingzong Li, Yu Li, Katarzyna A Ludwik, et al.
Organic Letters|November 6, 2014
De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101Roman M Mrozowski, Zachary M Sandusky, Rajender Vemula, et al.
Organic Letters|February 4, 2020
Regioselective Synthesis of a <i>C</i>-4'' Carbamate,<i>C</i>-6'' <i>n</i>-Pr Substituted Cyclitol Analogue of SL0101Yu Li, Zachary M Sandusky, Rajender Vemula, et al.
Cell Reports|July 23, 2020
RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor AlphaKatarzyna A Ludwik, Zachary M Sandusky, Kimberly M Stauffer, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101Mingzong Li, Yu Li, Roman M Mrozowski, et al.
Molecular Cancer Therapeutics|August 17, 2016
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast CancerKatarzyna A Ludwik, J Preston Campbell, Mingzong Li, et al.
JCI Insight|May 6, 2025
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancerShira Sherman, Zachary M Sandusky, Douglas Russo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Hematology/Oncology Clinics of North America|November 26, 2022
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerAlbert Grinshpun, Zachary M Sandusky, Rinath Jeselsohn
Biochimica Et Biophysica Acta. Reviews on Cancer|November 6, 2022
ESR1 activating mutations: From structure to clinical applicationAlbert Grinshpun, Vincent Chen, Zachary M Sandusky, et al.
STAR Protocols|January 25, 2021
FACS protocol for direct comparison of cell populations isolated from miceKatarzyna A Ludwik, Zachary M Sandusky, Eric B Wright, et al.
Organic Letters|April 26, 2017
Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2Mingzong Li, Yu Li, Katarzyna A Ludwik, et al.
Organic Letters|November 6, 2014
De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101Roman M Mrozowski, Zachary M Sandusky, Rajender Vemula, et al.
Organic Letters|February 4, 2020
Regioselective Synthesis of a <i>C</i>-4'' Carbamate,<i>C</i>-6'' <i>n</i>-Pr Substituted Cyclitol Analogue of SL0101Yu Li, Zachary M Sandusky, Rajender Vemula, et al.
Cell Reports|July 23, 2020
RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor AlphaKatarzyna A Ludwik, Zachary M Sandusky, Kimberly M Stauffer, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101Mingzong Li, Yu Li, Roman M Mrozowski, et al.
Molecular Cancer Therapeutics|August 17, 2016
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast CancerKatarzyna A Ludwik, J Preston Campbell, Mingzong Li, et al.
JCI Insight|May 6, 2025
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancerShira Sherman, Zachary M Sandusky, Douglas Russo, et al.
Pageof 1